Myelin-associated glycoprotein–ganglioside GM1 complex (MAG–GM1)

The Myelin-associated glycoprotein (MAG)–ganglioside GM1 interface is a specialized molecular junction between myelinating glia and the axonal membrane. MAG (Siglec-4) is a transmembrane protein expressed by oligodendrocytes and Schwann cells that recognizes and binds to specific sialic acid-containing glycosphingolipids, primarily gangliosides GM1 and GD1a, on the axonal surface (Vyas et al., 2002, Proc Natl Acad Sci U S A). This interaction plays a dual role: it maintains the physical stability of the periaxonal space in healthy nerves and serves as a major biochemical barrier to axonal regeneration following injury (Schnaar, 2004, Glycobiology). When myelin is damaged, MAG is released or exposed, and its binding to axonal GM1 triggers intracellular signaling pathways, such as RhoA activation, which lead to growth cone collapse and the inhibition of neurite outgrowth (Filbin, 2003, Nat Rev Neurosci). Therapeutic interventions, including monoclonal antibodies like GSK249320 and small-molecule sialic acid mimetics, are designed to disrupt this interface to facilitate nerve repair in conditions such as spinal cord injury and stroke (Cebere et al., 2011, Neurorehabil Neural Repair).

Other names

MAG-GM1 interfaceSiglec-4-GM1 interactionMyelin-associated glycoprotein-ganglioside interactionMAG-ganglioside complex

Antagonism of the inhibitory interaction between myelin-associated glycoprotein and axonal gangliosides to promote axonal regeneration and functional recovery after neural injury.